4592 Stock Overview Develops, produces, and sells regenerative cell medicines for the central nervous system. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
SanBio Company Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for SanBio Historical stock prices Current Share Price JP¥751.00 52 Week High JP¥1,489.00 52 Week Low JP¥380.00 Beta 0.43 1 Month Change -22.42% 3 Month Change -42.89% 1 Year Change 6.98% 3 Year Change -25.42% 5 Year Change -71.55% Change since IPO -57.64%
Recent News & Updates
New major risk - Revenue and earnings growth Dec 16 SanBio Company Limited announced that it expects to receive ¥1.99992672 billion in funding from Athos Capital Limited Dec 04
SanBio Company Limited Announces the Results of the First Commercial Production Run of AKUUGO Nov 17
SanBio Company Limited to Report Q3, 2025 Results on Dec 16, 2024 Oct 29
New major risk - Revenue and earnings growth Sep 18
Sanbio Co., Ltd. Obtains Marketing Approval for AKUUGO Suspension for Intracranial Implantation Jul 31 See more updates
New major risk - Revenue and earnings growth Dec 16 SanBio Company Limited announced that it expects to receive ¥1.99992672 billion in funding from Athos Capital Limited Dec 04
SanBio Company Limited Announces the Results of the First Commercial Production Run of AKUUGO Nov 17
SanBio Company Limited to Report Q3, 2025 Results on Dec 16, 2024 Oct 29
New major risk - Revenue and earnings growth Sep 18
Sanbio Co., Ltd. Obtains Marketing Approval for AKUUGO Suspension for Intracranial Implantation Jul 31
SanBio Company Limited to Report Q2, 2025 Results on Sep 17, 2024 Jul 27
Price target increased by 20% to JP¥960 Jul 01
Price target increased by 23% to JP¥983 Jun 20
New major risk - Revenue and earnings growth Jun 13
SanBio Company Limited Announces Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan Jun 13
SanBio Company Limited to Report Q1, 2025 Results on Jun 13, 2024 May 05
New major risk - Revenue and earnings growth Apr 02
Price target decreased by 30% to JP¥1,214 Mar 28
SanBio Company Limited, Annual General Meeting, Apr 24, 2024 Mar 19
SanBio Company Limited, Annual General Meeting, Apr 24, 2024 Mar 18
Price target increased by 18% to JP¥2,100 Mar 18
Forecast to breakeven in 2027 Jan 31
SanBio Company Limited to Report Fiscal Year 2024 Results on Mar 18, 2024 Jan 28
Sanbio Co., Ltd. Provides Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan Jan 25
New major risk - Financial position Dec 15
SanBio Company Limited Provides Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan Dec 14
SanBio Company Limited to Report Q3, 2024 Results on Dec 14, 2023 Oct 14
SanBio Company Limited to Report Q2, 2024 Results on Sep 15, 2023 Jul 29
Consensus revenue estimates fall by 15% Jul 28 SanBio Co., Ltd. Updates on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury Program in Japan
Price target increased by 13% to JP¥2,290 Jun 15
No longer forecast to breakeven Jun 01
SanBio Company Limited to Report Q1, 2024 Results on Jun 14, 2023 May 13
Price target increased by 12% to JP¥2,465 Mar 20
No longer forecast to breakeven Mar 16
Price target increased by 12% to JP¥2,465 Feb 20
SanBio Company Limited to Report Fiscal Year 2023 Results on Mar 16, 2023 Feb 03
Forecast to breakeven in 2026 Jan 31
SanBio Co., Ltd. Announces Board Changes Jan 20
SanBio Company Limited Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023 Dec 16
Less than half of directors are independent Nov 16
SanBio Company Limited to Report Q3, 2023 Results on Dec 15, 2022 Oct 01
Sanbio Company Limited Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023 Sep 14
Price target decreased to JP¥2,233 Jul 23
SanBio Company Announces Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan Jul 22
Keizo Nakada to Join Sanbio as Corporate Officer and Head of Production Jul 02
Price target decreased to JP¥2,200 Jun 24
SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year Ending January 31, 2023 Jun 14
SanBio Company Limited Appoints Andrew Liu as Chief Strategy Officer Jun 01
Less than half of directors are independent Apr 27
Sanbio Group Provides an Update on One-Year Analysis of the Phase 2 STEMTRA Trial Apr 06
Sanbio Company Limited Announces Filing with Japan’S Ministry of Health, Labour, and Welfare for Manufacture and Marketing Approval as A Regenerative Medicine Product for the Investigational Product Sb623 Mar 07
Price target increased to JP¥2,900 Feb 14 SanBio Company Limited announced that it expects to receive ¥33.75 million in funding from Nomura Securities Co., Ltd.
SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2022 Dec 17 SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2022
Corporate Officer & Business Head of Japan/Asia Hiroshi Yamamoto has left the company Jul 13
Price target increased to JP¥2,660 Jul 07
SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending January 31, 2022 Jun 15 SanBio Company Limited Provides Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending January 31, 2022
Sanbio Company Limited Presents STEMTRA Phase 2 Trial Results At the 44Th Annual Meeting of the Japan Society of Neurotraumatology Mar 01
SanBio Company Limited to Report Fiscal Year 2021 Results on Mar 17, 2021 Jan 28
SanBio Company Limited Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology Jan 06
Price target lowered to JP¥2,683 Dec 16
New 90-day low: JP¥1,388 Dec 16
Price target lowered to JP¥2,683 Dec 10
SanBio Company Limited to Report Q3, 2021 Results on Dec 15, 2020 Dec 05
Tokio Marine & Nichido Fire Insurance Co., Ltd. agreed to acquire 9.74% stake in CareNet, Inc. (TSE:2150) from SanBio Company Limited (TSE:4592). Dec 02
SanBio Company Limited Appoints Hiroyasu Narita as Head of Clinical Development, Effective from October 1, 2020 Oct 02
SanBio Company Limited to Report Q2, 2021 Results on Sep 14, 2020 Aug 10 Shareholder Returns 4592 JP Biotechs JP Market 7D -0.8% 3.9% 3.6% 1Y 7.0% 16.4% 16.3%
See full shareholder returns
Return vs Industry: 4592 underperformed the JP Biotechs industry which returned 16.4% over the past year.
Return vs Market: 4592 underperformed the JP Market which returned 16.3% over the past year.
Price Volatility Is 4592's price volatile compared to industry and market? 4592 volatility 4592 Average Weekly Movement 7.7% Biotechs Industry Average Movement 7.0% Market Average Movement 3.6% 10% most volatile stocks in JP Market 7.2% 10% least volatile stocks in JP Market 1.9%
Stable Share Price: 4592's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4592's weekly volatility has decreased from 16% to 8% over the past year, but is still higher than 75% of JP stocks.
About the Company SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.
Show more SanBio Company Limited Fundamentals Summary How do SanBio's earnings and revenue compare to its market cap? 4592 fundamental statistics Market cap JP¥51.54b Earnings (TTM ) -JP¥2.91b Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4592 income statement (TTM ) Revenue JP¥0 Cost of Revenue JP¥0 Gross Profit JP¥0 Other Expenses JP¥2.91b Earnings -JP¥2.91b
Last Reported Earnings
Oct 31, 2024
Earnings per share (EPS) -42.45 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 75.2%
How did 4592 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 20:49 End of Day Share Price 2024/12/30 00:00 Earnings 2024/10/31 Annual Earnings 2024/01/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources SanBio Company Limited is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Hidemaru Yamaguchi Citigroup Inc Miyabi Yamakita Jefferies LLC Stephen Barker Jefferies LLC
Show 9 more analysts 
